Clinical Trial Update: Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia [Phase 2]

View source ↗

Summary

A phase 2 clinical trial investigates using standard immunosuppressive therapy with Romiplostim as a first-line treatment for severe aplastic anemia; recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Aplastic Anemia, TPO Receptor Agonists | Phase 2 | Status: RECRUITING